ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

10:30AM-12:30PM: Abstract Number: 0049

Enhanced Src Homology Region 2 Domain-containing Phosphatase 1 Activity Ameliorates Murine Inflammatory Arthritis Through the Innate Immune System

(0049–0066) Rheumatoid Arthritis – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 0101

Enrichment of putative bacteria-reactive gut-derived IL-17+ tissue resident memory helper T cells in arthritic ankles in the SKG mouse model of spondyloarthritis

(0098–0114) Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 0551

Enthesitis Beyond the Surface: Ultrasonographic Unmasking of Preclinical Psoriatic Arthritis in Cutaneous Psoriasis

(0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0243

Epidemiology of adult-onset Systemic Autoinflammatory Diseases in a well-defined population from northern spain

(0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0722

Estimating two-year risk of relapse in individuals with ANCA-associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids

(0711–0730) Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: Abstract Number: 0310

Evaluate Safety, Tolerability, and Pharmacodynamics of a Single Intra-Articular Injection of GNSC-001 Gene Therapy in Subjects with Knee Osteoarthritis: 12-month Results from DONATELLO

(0306–0336) Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0138

Evaluating Artificial Intelligence for Diagnosing Antiphospholipid Syndrome in Pulmonary Embolism Case Reports: A Prompt-Based Analysis

(0115–0144) Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0614

Evaluating Cardiovascular Risk in Systemic Lupus Erythematosus: Comparing Novel Risk Scores with Carotid Ultrasound

(0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0530

Evaluating ChatGPT’s Performance in Diagnosing Low Back Pain: A Comparison with Clinicians and Impact of Prompted Specialties

(0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0339

Evaluating Discordance between Bilateral Hip Bone Density Measurements in Individuals with Low Bone Mass

(0337–0356) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0469

Evaluating Large Language Models for Automated Joint Involvement Analysis in Rheumatoid Arthritis

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0222

Evaluating the Barriers and Facilitators for Collecting and Documenting Rheumatoid Arthritis Disease Activity Measures Using a Rheumatology Provider Survey

(0210–0232) Measures & Measurement of Healthcare Quality Poster I

10:30AM-12:30PM: Abstract Number: 0531

Evaluating the Diagnostic Utility of 14-3-3 eta Autoantibodies in Axial Spondyloarthritis: A Multiplex Assay Approach

(0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0556

Evaluating the Efficacy of Sulfasalazine Compared to Placebo in the Treatment of Psoriatic Arthritis in Adults: A Systematic Review and Meta-Analysis

(0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0194

Evaluation of a Home-based Therapeutics Service: Feasibility, Patient and Caregiver Experience, and Cost

(0175–0198) Health Services Research Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].